[go: up one dir, main page]

DE60036881D1 - Neues nichtstrukturelles hcv polypeptid - Google Patents

Neues nichtstrukturelles hcv polypeptid

Info

Publication number
DE60036881D1
DE60036881D1 DE60036881T DE60036881T DE60036881D1 DE 60036881 D1 DE60036881 D1 DE 60036881D1 DE 60036881 T DE60036881 T DE 60036881T DE 60036881 T DE60036881 T DE 60036881T DE 60036881 D1 DE60036881 D1 DE 60036881D1
Authority
DE
Germany
Prior art keywords
polypeptides
new non
hcv polypeptide
polynucleotides
structural hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036881T
Other languages
English (en)
Other versions
DE60036881T2 (de
Inventor
Doris Chiron Corpo Coit
Angelica Chiron C Medina-Selby
Mark Chiron Corpo Selby
Michael Chiron Corpo Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22607625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60036881(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE60036881D1 publication Critical patent/DE60036881D1/de
Publication of DE60036881T2 publication Critical patent/DE60036881T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60036881T 1999-11-24 2000-11-22 Neues nichtstrukturelles hcv-polypeptid Expired - Lifetime DE60036881T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16750299P 1999-11-24 1999-11-24
US167502P 1999-11-24
PCT/US2000/032326 WO2001038360A2 (en) 1999-11-24 2000-11-22 Novel hcv non-structural polypeptide

Publications (2)

Publication Number Publication Date
DE60036881D1 true DE60036881D1 (de) 2007-12-06
DE60036881T2 DE60036881T2 (de) 2008-07-10

Family

ID=22607625

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036881T Expired - Lifetime DE60036881T2 (de) 1999-11-24 2000-11-22 Neues nichtstrukturelles hcv-polypeptid

Country Status (9)

Country Link
EP (1) EP1233982B1 (de)
JP (1) JP2003516732A (de)
KR (1) KR100788812B1 (de)
CN (2) CN101684146A (de)
AT (1) ATE376558T1 (de)
AU (1) AU2574601A (de)
CA (1) CA2390082C (de)
DE (1) DE60036881T2 (de)
WO (1) WO2001038360A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP1947185B1 (de) 2000-08-17 2011-07-20 Tripep Ab HCV NS3/4A kodierende Nukleinsäure
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
EP2172552A3 (de) 2001-10-11 2010-07-21 Merck Sharp & Dohme Corp. Rekombinante Nukleinsäuren beinhaltend Regionen von AD6
WO2003031588A2 (en) 2001-10-11 2003-04-17 Merck & Co., Inc. Hepatitis c virus vaccine
CN1678630A (zh) * 2002-07-02 2005-10-05 希龙公司 具有修饰的ns3结构域的hcv融合蛋白
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
ES2890882T3 (es) 2002-10-16 2022-01-24 Gen Probe Inc Composiciones y procedimientos para detectar el virus del Nilo occidental
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
CN1984677A (zh) * 2004-05-17 2007-06-20 希龙公司 截短的丙肝病毒ns5结构域以及含有该截短结构域的融合蛋白
EP1799868B1 (de) 2004-08-27 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Nichtstrukturelle hcv-proteinmutanten und verwendungsmöglichkeiten dafür
MX2007004662A (es) * 2004-10-18 2007-11-23 Globeimmune Inc Terapia basada en levaduras para infeccion cronica por hepatitis c.
EP2570423B1 (de) 2005-06-17 2023-05-03 MSD Italia S.r.l. Nukleinsäureimpfstoff für Hepatitis-C-Virus
CA2661492A1 (en) 2006-08-25 2008-02-28 Novartis Ag Hcv fusion polypeptides
EP2185195A2 (de) 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
ES2497016T3 (es) * 2009-03-30 2014-09-22 bioMérieux Soporte sólido de detección del VHC
CN102645534B (zh) * 2012-04-26 2015-08-12 杭州市萧山区第一人民医院 基于量子点编码微球芯片检测丙型肝炎病毒的方法
EP2968526A4 (de) 2013-03-14 2016-11-09 Abbott Lab Hcv-antigen-antikörper-kombinationstest sowie verfahren und zusammensetzungen zur verwendung darin
MX2015012824A (es) * 2013-03-14 2016-06-24 Abbott Lab Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
WO1991015771A1 (en) * 1990-04-04 1991-10-17 Chiron Corporation Combinations of hepatitis c virus (hcv) antigens for use in immunoassays for anti-hcv antibodies
EP0573624A4 (en) * 1991-11-07 1997-09-17 Baxter Diagnostics Inc Epitope mapping ot the c33c region of hcv
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
DE4428705A1 (de) * 1994-08-12 1996-02-15 Boehringer Mannheim Gmbh Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
US6143715A (en) * 1997-08-11 2000-11-07 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
US6211338B1 (en) * 1997-11-28 2001-04-03 Schering Corporation Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide
AU746258B2 (en) * 1998-01-30 2002-04-18 General Hospital Corporation, The Genetic immunization with nonstructural proteins of hepatitis C virus
JP4782927B2 (ja) * 1999-05-04 2011-09-28 ベーリンガー インゲルハイム （カナダ） リミテッド 代理細胞ベースシステム及びｃ型肝炎ウイルスｎｓ３プロテアーゼの活性を評価する方法

Also Published As

Publication number Publication date
WO2001038360A9 (en) 2002-12-12
CN101684146A (zh) 2010-03-31
WO2001038360A2 (en) 2001-05-31
JP2003516732A (ja) 2003-05-20
CA2390082A1 (en) 2001-05-31
AU2574601A (en) 2001-06-04
KR100788812B1 (ko) 2007-12-27
EP1233982A2 (de) 2002-08-28
CA2390082C (en) 2010-06-29
EP1233982B1 (de) 2007-10-24
WO2001038360A3 (en) 2002-03-07
DE60036881T2 (de) 2008-07-10
CN1425027A (zh) 2003-06-18
ATE376558T1 (de) 2007-11-15
KR20020065537A (ko) 2002-08-13

Similar Documents

Publication Publication Date Title
ATE376558T1 (de) Neues nichtstrukturelles hcv polypeptid
DE69518642D1 (de) Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c
NO905438L (no) Virusmiddel.
DE69830579D1 (de) Chimäre impfstoffe gegen flaviviren
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
GR3006171T3 (de)
SG165155A1 (en) Novel flavivirus antigens
ATE507312T1 (de) Nachweis und typisierung das hepatitis c virus (hcv) mittels 5'utr und ns5 nukleinsäuresequenzen
NZ518999A (en) Vaccine compositions
ATE206717T1 (de) Hcv-spezifische peptide, mittel dazu und ihre verwendung
AU6860891A (en) Non-a, non-b hepatitis virus genomic cdna and antigen polypeptide
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
DK1227323T3 (da) Ikke-A, ikke-B hepatitisvirusantigen, diagnostiske fremgangsmåder og vacciner
WO1995032290A3 (en) Non-a/non-b/non-c/non-d/non-e hepatitis agents and molecular cloning thereof
DE69928064D1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
DK0551275T3 (da) Non-A non-B sekvenser
ATE430167T1 (de) Humaner rekombinanter antikörper gegen das hepatitis c (hcv) nichtstrukturelles ns3 protein, nukleinsäure und deren verwendungen
WO2004039950A3 (en) Activation of hcv-specific cells
WO2000001718A3 (en) Ns4a-ns3 catalytic domain of hepatitis c
KR950000880A (ko) 한국형 씨(c)형 간염 바이러스의 일종인 케이에이치씨브이-엘2(khcv-l2)의 전체 뉴클레오티드서열 및 이로부터 유추된 아미노산 서열
KR950000881A (ko) 새로운 한국형 씨(C)형 간염 바이러스 씨디엔에이(cDNA) 절편의 뉴클레오티드 서열 및 이로부터 유추된 아미노산 서열
WO2004089978A3 (en) Use of hcv proteins

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: COIT, DORIS, EMERYVILLE, CALIF., US

Inventor name: MEDINA-SELBY, ANGELICA, EMERYVILLE, CALIF., US

Inventor name: SELBY, MARK, EMERYVILLE, CALIF., US

Inventor name: HOUGHTON, MICHAEL, EMERYVILLE, CALIF., US

8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted
8363 Opposition against the patent